Eraxis Dosage/Direction for Use

Specimens for fungal culture and other relevant laboratory studies (including histopathology) should be obtained prior to therapy to isolate and identify causative organism(s). Therapy may be instituted before the results of the cultures and other laboratory studies are known. However, once these results become available, antifungal therapy should be adjusted accordingly.
Adult patients: A single 200 mg loading dose should be administered on Day 1, followed by 100 mg daily thereafter. Duration of treatment should be based on the patient's clinical response. In general, antifungal therapy should continue for at least 14 days after the last positive culture.
Paediatric population (1 month to < 18 years) (dosing and treatment duration): A single loading dose of 3.0 mg/kg (not to exceed 200 mg) should be administered on Day 1 followed by a daily maintenance dose of 1.5 mg/kg (not to exceed 100 mg) thereafter.
Duration of treatment should be based on the patient's clinical response.
In general, antifungal therapy should continue for at least 14 days after the last positive culture.
The safety and efficacy of anidulafungin have not been established in neonates (< 1 month old) (see Precautions).
Water for injection presentation: Anidulafungin should be reconstituted with water for injection to a concentration of 3.33 mg/mL and subsequently diluted to a concentration of 0.77 mg/mL before use according to the instructions given in Special precautions for disposal and other handling under Cautions for Usage.
It is recommended that anidulafungin is administered at a maximum rate of infusion that does not exceed 1.1 mg/minute (see Precautions, Adverse Reactions and Special precautions for disposal and other handling under Cautions for Usage).
Renal and hepatic impairment: No dosing adjustments are required for patients with mild, moderate, or severe hepatic impairment. No dosing adjustments are required for patients with any degree of renal insufficiency, including those on dialysis. Anidulafungin can be given without regard to the timing of haemodialysis (see Pharmacology: Pharmacokinetics under Actions).
Other special populations: No dosing adjustments are required for adult patients based on patient gender, weight, ethnicity, HIV positivity, or geriatric status.